This website uses cookies to enhance the user experience.
||
M

MOWI GENETICS AS922 025 045

Research
Limited company
Sandviksbodene 77A 5035 BERGEN, Norge
Services
/ Research
/ 72.110 Research and experimental development on biotechnology

MOWI GENETICS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

CEO
RH

Roy Hjelmeland1977

Chairman of the board
JU

Joachim Ulsrud1990

Years since formation
6 years
since Jan 8, 2019
Type
Limited company
VAT registered
Yes
Number of employees
9

Ownership

Number of shares and share classes
10
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2024
27,609,154
NOK
Annual total result 2024
2,150,000
NOK
Total equity 2024
10,238,882
NOK
Last update: Jul 26, 2025

Management

Management / administration

NameRoleShares
RH

Roy Hjelmeland

1977

Managing Director/CEO-

Board

NameRoleShares
JU

Joachim Ulsrud

1990

Chairman-
RH

Roy Hjelmeland

1977

Board Member-

Others

NameRoleShares
E
ERNST & YOUNG AS
Auditor-
A
AZETS INSIGHT AS
Accountant-
Last update: Apr 13, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
M
MOWI HOLDING AS
Ordinary shares
10
100 %
Last update: Jun 2, 2025

Group structure

  • MOWI ASA
    Total operating income 2024: NOK 1,931,000,000
    Operating profit 2024: NOK 267,000,000
    Employees: 2632

Financials

in NOK

Summary

Year2024202320222021
Total operating income
27,609,154
99,138,695
38,743,863
38,323,859
Annual Total Result
2,150,000
46,870,286
-798,208
3,463,937
Total assets
27,831,569
83,078,103
22,907,632
19,075,268
Total liabilities
17,592,688
31,500,176
18,199,991
13,569,419
Total equity
10,238,882
51,577,927
4,707,641
5,505,849

P&L

Year2024202320222021
Total operating income
27,609,154
99,138,695
38,743,863
38,323,859
Total operating costs
24,556,734
39,320,849
39,136,258
33,720,634
Operating result
3,052,419
59,817,846
-392,395
4,603,224
Financial income/costs
-486,330
-453,657
-630,377
-347,430
Profit before tax
2,566,090
59,364,189
-1,022,772
4,255,794
Total tax & extraordinary income/cost
416,090
12,493,903
-224,564
791,857
Annual Total Result
2,150,000
46,870,286
-798,208
3,463,937

Balance overview

Year2024202320222021
Total fixed assets
407,346
478,083
724,231
619,558
Total current assets
27,424,223
82,600,020
22,183,401
18,455,710
Total assets
27,831,569
83,078,103
22,907,632
19,075,268
Short term debt
17,547,692
31,450,773
18,199,991
13,520,265
Long term debt
44,996
49,403
0
49,154
Total liabilities
17,592,688
31,500,176
18,199,991
13,569,419
Contributed capital
30,000
30,000
30,000
30,000
Retained earnings
10,208,882
51,547,927
4,677,641
5,475,849
Total equity
10,238,882
51,577,927
4,707,641
5,505,849
Total equity and liabilities
27,831,569
83,078,103
22,907,632
19,075,268

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology